secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001601830-26-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Q4 revenue $35.5M; first AI-driven clinical validation in FAP; cash runway to 2028
--------------------------------------------------------------------------------

- Q4 revenue $35.5M (up from $4.5M YoY); net loss $108.1M vs $178.9M; cash $753.9M.
- REC-4881 (MEK1/2) in FAP: 75% evaluable patients had reduced polyp burden at 12 weeks; 43% median reduction.
- Fifth Sanofi milestone ($4M) achieved Feb 2026; total $134M milestone payments received from Sanofi.
- 2026 cash operating expense guidance <$390M; cash runway into early 2028 without additional financing.
- REC-7735 (PI3Kα H1047R) shows >100-fold selectivity over WT; IND-enabling studies ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000038/0001601830-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000038/rxrx-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001601830-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer